Rimonci Capital

Venture Capital Active China Est. 2016
Visit website ↗ LinkedIn
Last updated 2026-06-18
Portfolio
7
in our dataset
Rounds participated
10
Rounds led
1
Rounds' value
$92.3M
total disclosed, rounds participated
Stages
Seed, Pre-Seed, A Round

About

Rimonci Capital is a venture capital firm focused on visual science innovation, investing in early-stage companies in ophthalmology, optometry, and neuro-ophthalmology across the U.S., Israel, Europe, and Greater China. Founded in 2016, it supports advancements in medical and IT solutions, leveraging its expertise and ecosystem to drive clinical and commercial success in the visual science field

Portfolio · 7

NovaSight
Eye-Tracking Based Solutions for Pediatric Vision Care
Led ★ 2 rounds $24.0M committed Latest: 2022-04
EyeYon Medical
Ophthalmic Products for Vision-threatening Conditions
2 rounds $33.0M committed Latest: 2021-03
EyeControl
Wearable Assistive Communication Device
1 round $7.5M committed Latest: 2020-08
BELKIN Vision
One-second Laser Treatment for Glaucoma
2 rounds $14.8M committed Latest: 2020-07
Galimedix Therapeutics
Novel Treatment for Neurodegenerative Diseases of the Eye and Brain
1 round $2.0M committed Latest: 2019-01
Eximore
Ophthalmic Drug Delivery
1 round $3.0M committed Latest: 2018-05
Addon Optics
Platform for Multifocal Lenses
1 round $8.0M committed Latest: 2018-05

Investment activity

2 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences8

Funds · 1

  • Rimonci Star Venture Capital — $20M Jun 2021

Q&A

What is Rimonci Capital's primary investment focus?
Rimonci Capital focuses on visual science innovation, investing in early-stage companies in ophthalmology, optometry, and neuro-ophthalmology.
Which sectors does Rimonci Capital primarily invest in?
Rimonci Capital's portfolio shows a strong concentration in the Health Tech & Life Sciences sector, with all 8 of its listed portfolio companies falling into this category.
Can you name some of Rimonci Capital's notable exits?
Rimonci Capital has had two notable exits: BELKIN Vision was acquired by Alcon Pharmaceuticals for $81M in July 2024, and 6over6 was acquired by 1-800 Contacts for $100M in December 2019.
What investment stages does Rimonci Capital typically target?
Rimonci Capital primarily invests in Seed, Pre-Seed, and A Round stages.
Which fund has Rimonci Capital raised?
Rimonci Capital raised the Rimonci Star Venture Capital fund in June 2021.
Who are the key individuals at Rimonci Capital?
Richel Liu is the CEO and a founder of Rimonci Capital, and Limin Wang serves as the Regional General Manager.
Where is Rimonci Capital headquartered?
Rimonci Capital is headquartered in Beijing, China.
What is an example of a recent investment by Rimonci Capital?
Rimonci Capital invested in NovaSight, a company developing eye-tracking based solutions for pediatric vision care, which raised an A Round of $38.88M.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)